Skip to main content

and
  1. Article

    Open Access

    Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association

    Non-ER nuclear receptor activity can alter estrogen receptor (ER) chromatin association and resultant ER-mediated transcription. Consistent with GR modulation of ER activity, high tumor glucocorticoid receptor...

    Eva Tonsing-Carter, Kyle M. Hernandez, Caroline R. Kim in Breast Cancer Research (2019)

  2. No Access

    Article

    A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

    Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis.

    Amikar Sehdev, Theodore Karrison, Yuanyuan Zha in Cancer Chemotherapy and Pharmacology (2018)

  3. Article

    Open Access

    Adjuvant ovarian function suppression and cognitive function in women with breast cancer

    To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.

    Kelly-Anne Phillips, Meredith M Regan, Karin Ribi in British Journal of Cancer (2016)

  4. Article

    Open Access

    Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion

    Varying the rate of continuous intravenous infusions of 5-fluorouracil (5FU) chemotherapy over a 24-hour period has been reported to improve patient outcomes. It has been hypothesized that circadian variation ...

    Gini F Fleming, Philip Schumm, Greg Friberg, Mark J Ratain, Uchenna O Njiaju in BMC Cancer (2015)

  5. No Access

    Article

    Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

    Etoposide is a widely used cytotoxic drug that is commercially available in both intravenous and oral formulations. High interpatient pharmacokinetic variability has been associated with oral etoposide adminis...

    Wei Peng Yong, Apurva A. Desai, Federico Innocenti in Cancer Chemotherapy and Pharmacology (2007)

  6. No Access

    Article

    A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer

    Carboxyamidotriazole (CAI) is a novel antineoplastic agent in clinical development with limited oral bioavailability. In vitro, ketoconazole has been demonstrated to inhibit CYP3A4-mediated metabolism of CAI. ...

    Apurva A. Desai, Federico Innocenti, Linda Janisch in Cancer Chemotherapy and Pharmacology (2004)

  7. No Access

    Article

    Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment

    Abstract

    Chetan Lathia, Gini F. Fleming, Mark Meyer in Cancer Chemotherapy and Pharmacology (2002)

  8. No Access

    Article

    Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil

    Aims: To determine the effect of food on the pharmacokinetics of 5-fluoruracil (5-FU) taken orally with eniluracil and to compare the performance of different pharmacokinetic analysis methods in the detection a p...

    Dale R. Shepard, Sridhar Mani, Helen Kastrissios in Cancer Chemotherapy and Pharmacology (2002)

  9. No Access

    Article

    Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations

    In previous phase I reports of short bolus infusion of rhizoxin, problems in assay sensitivity prevented the description of pharmacokinetic-pharmacodynamic relationships, and a pharmacologically guided approa...

    Boon C. Goh, Gini F. Fleming, Linda Janisch in Cancer Chemotherapy and Pharmacology (2000)

  10. No Access

    Article

    A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

    Purpose: To determine the feasibility, maximal tolerated doses, and response rates for a combined regimen of the platinum and 5-fluorouracil oral analogues bis-acetato-ammine-dichloro-cyclohexyl-amine platinum(I...

    Mark D. DeMario, Mark J. Ratain in Cancer Chemotherapy and Pharmacology (1999)

  11. No Access

    Article

    Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)

    Purpose: 9-Aminocamptothecin (9-AC) is a topoisomerase I inhibitor with high antitumor activity but poor solubility in conventional vehicles. The purpose of this study was to evaluate the toxicities and pharmaco...

    Sridhar Mani, Lalitha Iyer, Linda Janisch in Cancer Chemotherapy and Pharmacology (1998)

  12. No Access

    Article

    Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein

    We evaluated the multidrug resistance (MDR)-modulating effects of progesterone (PRG) and an orally active, structurally related compound, megestrol acetate (MA), in several MDR human cell lines. At 100 μm, both s...

    Gini F. Fleming, Jacqueline M. Amato in Cancer Chemotherapy and Pharmacology (1992)

  13. No Access

    Article

    Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis

    We conducted a double-blind, randomized crossover study to compare the toxicity and antiemetic efficacy of the 5-hydroxytryptamine3 receptor antagonist batanopride with that of metoclopramide in 21 chemotherapy-n...

    Gini F. Fleming, Everett E. Vokes in Cancer Chemotherapy and Pharmacology (1991)